Man Group plc Makes New $2.82 Million Investment in LeMaitre Vascular, Inc. $LMAT

Man Group plc acquired a new stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 29,417 shares of the medical instruments supplier’s stock, valued at approximately $2,823,000.

A number of other hedge funds also recently made changes to their positions in LMAT. Sound Income Strategies LLC lifted its position in shares of LeMaitre Vascular by 425.6% during the first quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 183 shares in the last quarter. Catalyst Capital Advisors LLC acquired a new stake in LeMaitre Vascular during the 1st quarter valued at $32,000. Geneos Wealth Management Inc. grew its holdings in LeMaitre Vascular by 250.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 398 shares in the last quarter. EverSource Wealth Advisors LLC purchased a new stake in LeMaitre Vascular during the 2nd quarter worth $47,000. Finally, Quarry LP lifted its holdings in LeMaitre Vascular by 267.2% in the 3rd quarter. Quarry LP now owns 727 shares of the medical instruments supplier’s stock worth $64,000 after buying an additional 529 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Stock Down 0.2%

NASDAQ:LMAT opened at $80.28 on Tuesday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 13.96 and a current ratio of 16.31. The company has a market capitalization of $1.84 billion, a price-to-earnings ratio of 28.17, a price-to-earnings-growth ratio of 2.32 and a beta of 0.53. LeMaitre Vascular, Inc. has a one year low of $78.27 and a one year high of $118.01. The stock has a 50-day simple moving average of $92.88 and a 200 day simple moving average of $99.36.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 EPS for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.07). LeMaitre Vascular had a return on equity of 15.63% and a net margin of 25.02%.The firm had revenue of $70.38 million for the quarter, compared to the consensus estimate of $71.47 million. During the same period in the prior year, the business earned $0.60 EPS. The company’s quarterly revenue was up 9.6% on a year-over-year basis. Sell-side analysts predict that LeMaitre Vascular, Inc. will post 2.89 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 3rd. Shareholders of record on Thursday, August 20th will be issued a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date of this dividend is Thursday, August 20th. LeMaitre Vascular’s payout ratio is currently 35.09%.

Analyst Upgrades and Downgrades

LMAT has been the subject of a number of analyst reports. Citizens Jmp upped their price objective on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the company a “market outperform” rating in a research report on Wednesday, May 6th. Barrington Research cut LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 5th. Wall Street Zen downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Zacks Research downgraded LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Finally, Wells Fargo & Company cut their target price on LeMaitre Vascular from $104.00 to $94.00 and set an “equal weight” rating on the stock in a research report on Wednesday, August 5th. Three research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, LeMaitre Vascular currently has a consensus rating of “Hold” and a consensus price target of $110.60.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.